If you would like to learn more about future focusIR related events and roundtables, please submit your details here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCalculus Vct Regulatory News (CLC)

Share Price Information for Calculus Vct (CLC)

Share Price is delayed by 15 minutes
Get Live Data
53.25    0.00 (0.00%)
Bid:
48.00
Ask:
58.50
Spread: 10.50 (21.875%)
Market Cap: £52.20m
CLC Live PriceLast checked at - London Stock Exchange

Intraday Calculus Vct Share Chart

Release of clinicalvision V

23 Dec 2008 09:53

RNS Number : 6676K
Clinical Computing PLC
23 December 2008
 



CLINICAL COMPUTING PLC

Releases its newest product clinicalvision V, a fully web-enabled, enterprise class clinical information system 

Clinical Computing Plc ("the Company"), the international developer of clinical information systems for the healthcare market and developer of programme management software, announces the immediate release of clinicalvision V.

This new product release

 

·; Addresses the market requirement for a complete web based healthcare solution
·; Further strengthens partner and new customer sales opportunities
·; Includes a number of new interfaces and reporting modules.

The market 

With a growing need for remote and extended care for patients with chronic diseases, this product is aimed at providing a low cost solution to capture information anywhere and at any time. Comprehensive medical records are maintained which ensures that health service providers are accurately compensated for new and traditional care practices provided in a care centre, hospital or in the community.

Technology

This product is the culmination of several years of development effort to create an enterprise class software platform. It has been developed in Java and hosted on standard internet technologies. A primary focus of the move to this new technology was to provide a platform supporting seamless communication protocols with other common devices, which are benefiting from the internet, such as handheld mobile devices and smart-phones. 

Partners and customers

This release will allow our customers and their patients to benefit from the power and low cost nature of the internet by combining the highest levels of internet security with the ability to capture clinical documentation and patient information any time anywhere.

Clinicalvision V's new interface engine will allow the Company to rapidly develop electronic connections to other critical technologies in use by medical professionals, thus enhancing support of the clinical workflow process and reducing the cost of collecting information.

 

The Company's ability to interface with medical devices via this new interface engine compliments our partnership strategy and permits us to rapidly build new communication interfaces with selected partners.

Chairman Howard Kitchner, commenting said:

"With the release of clinicalvision V your Company has achieved a significant milestone in its evolution and now has a leading internet based clinical information system supporting evidence based medicine and secure electronic patient records. The first release of clinicalvison V will be implemented with several of our North American customers beginning in the new year. We expect to implement this new technology in our European sites later in 2009." 

 

Contacts:

Joe Marlovits, Chief Executive, Clinical Computing

www.ccl.com 

020 3006 7537

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
NRAKXLBLVLBXFBX
Date   Source Headline
29th Jun 20264:59 pmRNSIssue of Equity
22nd Apr 20263:39 pmRNSTransaction in Own Shares
31st Mar 20265:55 pmRNSDirectorate change
25th Mar 20262:23 pmRNSIssue of Equity
18th Feb 20263:14 pmRNSIssue of Equity
22nd Jan 20269:29 amRNSTransaction in Own Shares
16th Jan 20264:34 pmRNSNet Asset Value(s)
14th Jan 20263:00 pmRNSDividend Declaration
18th Dec 20252:30 pmRNSIssue of Equity
18th Dec 20252:30 pmRNSIssue of Equity
17th Dec 20253:15 pmRNSIssue of Equity
15th Dec 20253:10 pmRNSHalf-year Financial Report
14th Oct 20254:33 pmRNSTransaction in Own Shares
3rd Oct 202511:42 amRNSPublication of a Prospectus
2nd Oct 20254:29 pmRNSIssue of Equity
24th Sep 202511:22 amRNSResult of AGM & Change in Directorship
2nd Sep 20252:48 pmRNSIssue of Equity
28th Aug 202512:38 pmRNSPublication of Supplementary Prospectus
27th Aug 20252:52 pmRNSNet Asset Value
31st Jul 20259:46 amRNSAnnual Report with updated dividend details
30th Jul 202511:31 amRNSAnnual Financial Report &Related Party Transaction
3rd Jul 20259:17 amRNSIssue of Equity
10th Jun 20254:41 pmRNSTransaction in Own Shares
5th Jun 20254:39 pmRNSTransaction in Own Shares
4th Apr 20255:15 pmRNSIssue of Equity
26th Mar 20253:21 pmRNSIssue of Equity
11th Mar 20255:11 pmRNSChange of auditor
20th Feb 20254:30 pmRNSIssue of Equity
12th Feb 20254:39 pmRNSTransaction in Own Shares
21st Jan 20255:11 pmRNSNet Asset Value(s)
10th Jan 20253:46 pmRNSIssue of Equity update
18th Dec 20244:24 pmRNSIssue of Equity - 18 December 2024
5th Dec 20245:25 pmRNSHalf-year Report
14th Oct 20241:40 pmRNSPublication of a Prospectus
8th Oct 20245:23 pmRNSTransaction in Own Shares
9th Sep 202411:48 amRNSStatement re Intention to Fund Raise
29th Aug 20245:32 pmRNSIssue of Equity
22nd Aug 20244:27 pmRNSResults of Annual General Meeting
31st Jul 20245:44 pmRNSIssue of Equity
17th Jul 20241:51 pmRNSNet Asset Value(s)
11th Jul 20245:38 pmRNSAnnual Financial Report
24th Apr 20244:49 pmRNSTransaction in Own Shares
5th Apr 20242:54 pmRNSIssue of Equity - 5 April 2024
22nd Feb 20244:38 pmRNSDirectorship Change
15th Feb 202411:53 amRNSIssue of Equity - 15 February 2024
1st Feb 20244:38 pmRNSNet Asset Value - 31 December 2023
10th Jan 20245:27 pmRNSTransaction in Own Shares
21st Dec 202310:08 amRNSDirectorate Change
15th Dec 20233:25 pmRNSIssue of Equity - 15 December 2023
20th Nov 20232:11 pmRNSSeptember 2023 NAV Announcement

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.